twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2007
vol. 109
 
Share:
Share:
abstract:
Original paper

Pegaptanib sodium in treatment of choroidal neovascularization secondary to age-related macular degeneration. One year results

Halina Wykrota
1
,
Urszula Gajdzik-Gajdecka
1
,
Krzysztof Trzciąkowski
1
,
Magdalena Smużyńska
1

  1. Samodzielny Publiczny Szpital Kliniczny Nr 5 Śląskiego Uniwersytetu Medycznego w Katowicach
Klinika Oczna 2007, 109 (4): 394-401
Online publish date: 2007/12/20
View full text Get citation
 
Purpose
Prospective, noncomparative (nonrandomized, uncontrolled), consecutive interventional case series study - to evaluate the efficacy of intravitreal pegaptanib sodium in the treatment of choroidal neovascularization due to age-related macular degeneration in treatment-naive patients.

Material and methods
38 eyes of 38 patients were treated with intravitreal pegaptanib. All angiographic subtypes of lesions were qualified to the treatment. Intravitreal injections were performed every 6 weeks at the discretion of the treating ophthalmologist. Retreatment criteria were based on evaluation of presence of submacular fluid and/or increase in macular thickness seen in OCT, new retinal hemorrhage, and loss of visual acuity (VA).

Results
The VA outcomes were assessed at 48-th week of the study. The mean change in VA for all lesions was a loss of 9.4 ETDRS letters. Percent of patients losing less than 15 ETDRS letters in predominantly classic subgroup was 68%, minimally classic – 65% and pure occult – 72%. 7% of patients gained more than 1 ETDRS lines of VA whereas 2% more than 3 ETDRS lines. 8.5% of patients lost 30 and more ETDRS letters at 48-th week of the study. Results were better for smaller (<4 DA) lesions, eyes with better (> 54 ETDRS letters) baseline VA and for pure occult lesions.

Conclusions
Pegaptanib sodium effectively preserve vision in approximately 70% of patients with wet AMD in 1-year period of observation. Eyes with more advanced lesions seen at baseline have an increased risk of worse VA outcomes.

keywords:

choroidal neovascularization age-related macular degeneration, pegaptanib sodium, vascular endothelial growth factor

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.